Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030.

IF 9.7 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

EBioMedicine Pub Date : 2024-11-04 DOI:10.1016/j.ebiom.2024.105424

Mateusz Hasso-Agopsowicz, Angela Hwang, Maria-Graciela Hollm-Delgado, Isis Umbelino-Walker, Ruth A Karron, Raman Rao, Kwaku Poku Asante, Meru Sheel, Erin Sparrow, Birgitte Giersing

{"title":"Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030.","authors":"Mateusz Hasso-Agopsowicz, Angela Hwang, Maria-Graciela Hollm-Delgado, Isis Umbelino-Walker, Ruth A Karron, Raman Rao, Kwaku Poku Asante, Meru Sheel, Erin Sparrow, Birgitte Giersing","doi":"10.1016/j.ebiom.2024.105424","DOIUrl":null,"url":null,"abstract":"Background: To date, global priorities for new vaccine R&D have not been systematically identified for endemic pathogens. As part of Immunisation Agenda 2030 (IA2030), we have systematically identified priority endemic pathogens for new vaccine R&D based on country and regional stakeholder values to address this need.Methods: MCDA surveys targeting policy makers and immunisation stakeholders in each World Health Organization (WHO) region were used to weight eight criteria for prioritisation. Applying those weights to regional pathogen data yielded regional top ten pathogen lists, which are intended to inform regional deliberations on R&D priorities. The regional top ten lists were combined into an IA2030 global priority list. To inform R&D, use cases for new vaccines and monoclonal antibodies were identified, then categorized in terms of the activities needed to accelerate progress.Findings: In five out of six WHO regions, Annual deaths in children under five and Contribution to antimicrobial resistance were the most heavily weighted criteria. How participants weighted the criteria was not associated with their region, biographical characteristics, or areas of expertise. Five pathogens were common priorities across all regions: M tuberculosis, HIV-1, K pneumoniae, S aureus, and Extra-intestinal pathogenic E coli. Six pathogens were priorities in single regions. Combining regional top ten lists provided a global list of 17 priority pathogens for new vaccine R&D. Thirty-four distinct use cases were identified for new products targeting these pathogens. While most are in the \"Advance product development\" category, ten are in the \"Research\" category and seven are in the \"Prepare to implement\" category.Interpretation: These priorities for new vaccine R&D will help stakeholders better respond to regional and country needs. The use cases will inform R&D and enable monitoring of R&D under IA2030.Funding: The work was funded by a Bill and Melinda Gates Foundation grant to WHO (INV-005318).","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":" ","pages":"105424"},"PeriodicalIF":9.7000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EBioMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ebiom.2024.105424","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To date, global priorities for new vaccine R&D have not been systematically identified for endemic pathogens. As part of Immunisation Agenda 2030 (IA2030), we have systematically identified priority endemic pathogens for new vaccine R&D based on country and regional stakeholder values to address this need.

Methods: MCDA surveys targeting policy makers and immunisation stakeholders in each World Health Organization (WHO) region were used to weight eight criteria for prioritisation. Applying those weights to regional pathogen data yielded regional top ten pathogen lists, which are intended to inform regional deliberations on R&D priorities. The regional top ten lists were combined into an IA2030 global priority list. To inform R&D, use cases for new vaccines and monoclonal antibodies were identified, then categorized in terms of the activities needed to accelerate progress.

Findings: In five out of six WHO regions, Annual deaths in children under five and Contribution to antimicrobial resistance were the most heavily weighted criteria. How participants weighted the criteria was not associated with their region, biographical characteristics, or areas of expertise. Five pathogens were common priorities across all regions: M tuberculosis, HIV-1, K pneumoniae, S aureus, and Extra-intestinal pathogenic E coli. Six pathogens were priorities in single regions. Combining regional top ten lists provided a global list of 17 priority pathogens for new vaccine R&D. Thirty-four distinct use cases were identified for new products targeting these pathogens. While most are in the "Advance product development" category, ten are in the "Research" category and seven are in the "Prepare to implement" category.

Interpretation: These priorities for new vaccine R&D will help stakeholders better respond to regional and country needs. The use cases will inform R&D and enable monitoring of R&D under IA2030.

Funding: The work was funded by a Bill and Melinda Gates Foundation grant to WHO (INV-005318).

查看原文本刊更多论文

利用多标准决策分析（MCDA）确定世卫组织全球疫苗研发（R&D）的优先流行病原体：《2030 年免疫议程》的目标。

背景：迄今为止，全球尚未系统地确定地方性病原体的新疫苗研发重点。作为《2030 年免疫议程》（IA2030）的一部分，我们根据国家和地区利益相关者的价值观，系统地确定了新疫苗研发的优先流行病原体，以满足这一需求：方法：针对世界卫生组织（WHO）各地区的政策制定者和免疫接种利益相关者开展 MCDA 调查，对确定优先次序的八项标准进行加权。将这些权重应用于地区病原体数据，得出地区十佳病原体名单，旨在为地区研发优先事项审议提供信息。地区十大病原体名单被合并为 IA2030 全球优先名单。为了给研发工作提供信息，我们确定了新型疫苗和单克隆抗体的使用案例，然后根据加速进展所需的活动进行了分类：在世界卫生组织六个地区中的五个地区，五岁以下儿童年死亡人数和对抗生素耐药性的贡献是权重最高的标准。参与者如何给标准加权与他们所在的地区、个人特点或专业领域无关。有五种病原体是所有地区的共同优先选择：结核杆菌、HIV-1、肺炎双球菌、金黄色葡萄球菌和肠道外致病性大肠杆菌。有六种病原体是单一地区的优先病原体。综合各地区的前十名病原体名单，得出了 17 种新疫苗研发优先病原体的全球名单。针对这些病原体的新产品确定了 34 种不同的用例。虽然大多数属于 "推进产品开发 "类，但有十种属于 "研究 "类，七种属于 "准备实施 "类：这些新疫苗研发的优先事项将帮助利益相关者更好地满足地区和国家的需求。这些用例将为研发提供信息，并有助于监测 IA2030 下的研发工作：这项工作由比尔及梅林达-盖茨基金会向世卫组织提供的赠款（INV-005318）资助。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EBioMedicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

17.70

自引率

0.90%

发文量

579

审稿时长

5 weeks

期刊介绍： eBioMedicine is a comprehensive biomedical research journal that covers a wide range of studies that are relevant to human health. Our focus is on original research that explores the fundamental factors influencing human health and disease, including the discovery of new therapeutic targets and treatments, the identification of biomarkers and diagnostic tools, and the investigation and modification of disease pathways and mechanisms. We welcome studies from any biomedical discipline that contribute to our understanding of disease and aim to improve human health.